



PC10240A/EDJ

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

MCCLURE ET AL.

: Examiner: Weber, J.

SERIAL NO.: 09/373,182

: Art Unit: 1651

FILED: AUGUST 12, 1999

FOR: TACE INHIBITORS

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

RECEIVED  
FEB 06 2002  
TECH CENTER 1600/2900

11/B  
P.93  
2/8/02

Sir:

AMENDMENT

This document responds to an Office Action mailed July 11, 2001, requiring a response by October 11, 2001. A Petition for a two-month extension of time accompanies this document. If such Petition is granted the period in which to respond will expire on December 11, 2001.

CLEAN COPY - ENTER

In the Specification:

Please delete the paragraph at page 41, lines 26-32, and replace such deleted paragraph with the following paragraph:

B<sup>1</sup> A model peptidic TNF- $\alpha$  substrate (LY-LeucineAlanineGlutamineAlanineValine-ArginineSerine-SerineLysine(CMTR)-Arginine (LY=Lucifer Yellow; CMTR= 5-carboxytetramethyl Rhodamine)) (hereinafter SEQ ID No: 4) was prepared and the concentration estimated by absorbance at 560 nm (E560, 60,000 M-1CM-1) according to the method of Geoghegan, KF, "Improved method for converting an unmodified peptide to an energy-transfer substrate for a proteinase." Bioconjugate Chem. 7, 385-391 (1995). This peptide encompasses the cleavage site on pro-TNF which is cleaved in vivo by TACE.

Please delete the paragraph at page 43, Table A, Row 3, and replace such deleted row with the following row: